---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004070"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:37:01.450615+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences reports FY 2024 net income $2.8M; Phase 1b PRECISE-AD enrolling

## Summary
- Cash $13.3M at Dec 31, 2024; PIPE financing provided $30.3M upfront with potential $92.4M from warrants.
- R&D expenses $10.6M (up 34% YoY) driven by Phase 1a/1b clinical costs; net income of $2.8M vs loss of $13.2M in 2023.
- Gain on change in fair value of warrant liabilities of $22.6M drove net income; operating loss remains.
- Phase 1b PRECISE-AD trial (NCT06750432) dosed multiple patients; plans ~100 subjects at 22 US sites.
- Interim results from PRECISE-AD expected 1H 2026, topline results by end of 2026.

## SEC filing metadata
- accession: 0001558370-25-004070
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/0001558370-25-004070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004070
- JSON: https://secwatch.observer/filing/0001558370-25-004070.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.